India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...